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Patients suﬀering from spinal cord injuries resulting in complete or incomplete paraplegia or tetraplegia are highly dis-
posed to frequent, recurrent or even chronic urinary tract infections (UTIs). The reason for the increased risk of acquir-
ing UTIs is multifactorial, including reduced sensation of classical UTI symptoms, incomplete bladder emptying,
frequent catheterizations or chronic urinary tract catheters. Bioﬁlms in relation to UTIs have been shown both on
catheters, on concrements or as intracellular bacterial communities (IBCs). Due to the increased risk of acquiring recur-
rent or chronic UTIs and frequent antibiotic treatments, patients experience an increased risk of being infected with
antibiotic-resistant bacteria like extended-spectrum b-lactamase–producing Escherichia coli or Klebsiella spp., but also
bacteria like Pseudomonas aeruginosa inherently resistant to several antibiotics. Diagnosing the UTI can also be chal-
lenging, especially distinguishing harmless colonization from pathogenic infection. Based on a previous study showing
activation of humoral immune response toward UTI pathogens in patients with spinal cord lesions (SCL), the present
mini review is an evaluation of using antibody response as an indicator of chronic bioﬁlm UTI. In addition, we evalu-
ated the eﬀect of long-term treatment with antibiotics in patients with SCLs and chronic UTI, deﬁned by culturing of a
uropathogen in the urine and elevated speciﬁc precipitating antibodies against the same uropathogen in a blood sample.
Elimination of chronic UTI, decrease in speciﬁc precipitating antibody values and avoiding selection of new multidrug-
resistant (MDR) uropathogens were the primary markers for eﬀect of treatment. The results of this evaluation suggest
that the long-term treatment strategy in SCL patients with chronic UTI may be eﬀective; however, randomized
prospective results are needed to conﬁrm this.
Key words: Spinal cord lesion; chronic urinary tract infection; antibiotic treatment; speciﬁc precipitating antibodies;
multidrug-resistant uropathogens.
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Urinary tract infection (UTI) is the most frequent
medical complication in patients with spinal cord
lesions (SCLs) (1). In the past, renal failure and
other urinary tract complications were the primary
cause of death in this group of patients. During the
past 30 years, the causes of death have become
more similar to those of the general population
(2, 3). However, UTIs are the most frequent cause
of hospitalization in this population (4, 5) and
recurrent or chronic UTIs might in part be respon-
sible for reduced renal function (6). In addition, the
pathogens cultured from the SCL patients become
increasingly resistant and thereby increasingly diﬃ-
cult to treat, in some cases due to the developmentReceived 9 January 2017. Accepted 3 February 2017
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of hypermutating isolates (7, 8). Moreover, the risk
of acquiring an UTI with a resistant isolate is sig-
niﬁcantly increased if previous UTI(s) had been
caused by resistant isolates (9). However, if time
between positive cultures increased, reduced risk
repeated identiﬁcation of the resistant phenotype
was observed (9).
Both the spinal cord lesion and the bladder drai-
nage methods increase the risk of UTI and often
lead to a lack of classical UTI symptoms. The fre-
quency of UTI depends on the drainage method,
indwelling catheters being responsible for most
cases of UTIs (2, 10, 11). The uropathogen might
form a bioﬁlm either on the surface of a catheter,
in concrements or in the bladder epithelia (4, 12,
13) and can then survive signiﬁcantly higher con-
centrations of, and standard length of treatments
with, antibacterial agents than usual and thereby
cause chronic infections. There is no general con-
sensus on how these chronic bioﬁlm infections
should be treated. The use of long-term treatment
with antibacterial agents in bioﬁlm infections is well
known and accepted in patients with cystic ﬁbrosis
(CF) (14, 15). In this study, we apply this knowl-
edge to another group of patients, the SCL
patients, and analyze the eﬀects of long-term treat-
ment with antibacterial therapy in the management
of chronic UTIs. Also, the use of measuring speciﬁc
precipitating antibodies as a diagnostic and moni-
toring tool was applied (6). Elimination of chronic
UTI, decrease in precipitating antibody values and
avoiding selection of new multidrug-resistant
(MDR) uropathogens were the primary markers for
eﬀect of treatment.
EVALUATION OF TREATMENT STRATEGY
We evaluated the incidence of chronic UTIs and
the eﬀect of long-term treatment with antibiotics in
patients at the Clinic for Spinal Cord Injuries,
Rigshospitalet, Copenhagen University Hospital.
All patients who had a chronic UTI between May
2005 and April 2008 underwent evaluation. Infor-
mation of these patients was sent to the Depart-
ment of Microbiology for counseling concerning
antibiotic therapy. Each patient was only included
once with his or her latest chronic UTI (in the
study period), but in cases where patients were
chronically infected with more than one microor-
ganism, both isolates were included.
Elimination of the chronic UTI, decrease in pre-
cipitating antibody values and avoiding selection of
new MDR uropathogens were the primary markers
for eﬀect of treatment, comparing patients treated
in accordance with the recommendations from the
Department of Microbiology and patients not trea-
ted in accordance with this. No ethical approval
was required for this evaluation.
DEFINITIONS
For the novel treatment strategy and to be able to
evaluate the eﬀect, we had deﬁned a chronic UTI.
UTI was deﬁned as chronic when uropathogens
were found in the urine culture and there were
increased levels of precipitating antibodies speciﬁc
to this uropathogen in at least one blood sample
detected by crossed immunoelectrophoresis using
water-soluble antigens obtained by sonication
and counting the number of immunoprecipitates
(= number of precipitating antibodies) as detailed
previously (6, 16, 17). The diagnosis was supported
by ﬁndings of the same uropathogen several times,
reduction in renal function and recurrent UTI
symptoms. The physician taking the clinical history
assessed the symptoms. The patients were all asked
if they had already been treated with antibiotics, if
so this was taken into account in the counseling.
No patients received antibiotic treatment when the
urine sample was taken. The clinical routine con-
cerning bladder stones was to screen the patients
with stone-CT-scan and isotope renography every
2 years and if clinical suspicion of stones the CT-
scan may have been repeated before the 2-year
mark. Nearly all the patients have had urodynamic
investigations performed, the bladder emptying
method was described according to the Interna-
tional SCI Lower Urinary Tract Basic Data Set
(18).
The present evaluation was performed before the
International SCI Urinary Tract Infection Basic
Data Set had been developed (19).
Reduction in renal function is noted as a decline
in corrected chrome EDTA glomerular ﬁltration
rate. All patients in the clinic has this value mea-
sured every second year.
The normal value of precipitating antibodies to
Escherichia coli and Klebsiella sp. is 0–2 precipitins,
for Pseudomonas aeruginosa the normal value is 0–1
precipitins as reported previously (6). The normal
values reﬂect what can be seen in the background
population. Precipitating antibodies are only
formed during chronic infections and vanish very
slowly over the course of months to years. A value
exceeding the normal values therefore indicates pre-
vious or present chronic infections with the patho-
gens to which they are directed (6).
Signiﬁcant bacteriuria was deﬁned as 103 CFU/
mL [lower in case of classic UTI symptoms (dy-
suria, frequency and urgency) and increased levels
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of speciﬁc precipitating antibodies]. MDR was
deﬁned as acquired non-susceptibility to two or
more groups of antibacterial agents (penicillins,
cephalosporins, carbapenems, ﬂuoroquinolones,
aminoglycosides, sulfonamides and polymyxins)
that the uropathogen is normally susceptible to.
The present evaluation was performed before the
international expert proposal for interim standard
deﬁnitions for antibiotic acquired resistance was
published (20).
TREATMENT REGIMES
The recommendations from the Department of
Microbiology concerning UTIs in patients with
SCLs were the following: non-chronic UTIs were
treated with relevant antibacterial therapy for 10–
14 days. Chronic UTIs with uropathogens with
normal susceptibility were treated initially with one
type of antibacterial therapy (often beta-lactam
antibiotics) for 5–7 days followed by 3–4 weeks of
treatment with another type of antibacterial therapy
(preferably ﬂuoroquinolones if the microorganism
was susceptible to this). Some patients might have
been treated for non-chronic UTI before they
developed chronic UTI.
Chronic UTIs withMDR bacteria or any of the fol-
lowing uropathogens (Proteus sp., Pseudomonas sp.,
Serratia sp. or Acinetobacter sp.) were treated simi-
larly. Initially, they were treated with a combination
of two types of antibiotics with diﬀerent antibacterial
killing mechanism (e.g., beta-lactam antibiotics inhi-
bit cell wall biosynthesis whereas ﬂuoroquinolones
inhibit the DNA synthesis) and to which the pathogen
was susceptible for 5–7 days, if necessary including
hospitalization. This was followed by treatment with
another group of antibiotic for 4 weeks (often
ﬂuoroquinolones if the microorganism was suscepti-
ble to this). If the pathogen was only susceptible to
the two groups of antibiotics used in the initial treat-
ment, the treatment was continued with one of these,
most often beta-lactam antibiotics.
A detailed drug history could not be obtained
for all patients and it is possible that some patients
have received antibiotic treatment other than that
recommended; however, in this analysis, we only
included patients who were followed up regularly at
the Clinic for Spinal Injuries. All these patients
were asked whether they had received any other
antibiotic treatment.
All indwelling catheters were recommended to be
replaced 2 days after treatment was initiated. If uri-
nary tract stones were present, long-term antibiotic
treatment was not recommended. The primary
treatment was removal of the stones, sometimes in
combination with antibiotic treatment.
STATISTICS
The data were analyzed using Microsoft Excel and
Prism6. The Mann–Whitney test was used for the
analysis of inter-group comparisons of continuous
data. For the analysis of inter-group comparisons
of categorical data, the chi-square test or Fisher’s
exact test was used. For analysis of intra-group
data, the paired t-test was used. A p-value
of < 0.05 was considered as statistically signiﬁcant.
RESULTS
In total, 129 patients were deﬁned as chronically
infected; of these, nine patients had two microor-
ganisms signiﬁcant for chronic urine infection and
Table 1. Demographic data
Entire cohort
(n = 129)
Treated
(n = 81)
Non-treated
(n = 27)
Probably
treated (n = 7)
Probably non-treated
(n = 6)
No data
(n = 12)
Patients, gender, male/female
94/35 59/22 19/8 6/ 1 9
Age, median (min–max)
53 (16–94) 53 (18–94) 50 (16–71) 58 (20–66) 55.5 (47–64) 47 (26–82)
Duration of spinal cord lesion, years, median (min–max)
21 (1–73) 21 (2–73) 21 (1–48) 28 (19–41) 16 (6–26) 27 (7–41)
Cause of spinal cord injury, n (%)
Traumatic 42 27 7 3 1 4
Innate 26 17 6 1 0 2
Other 37 22 9 2 1 3
The patients are divided into ﬁve groups, treated and non-treated, according to the recommendations from the Department
of Microbiology. Probably treated and probably non-treated when some data were missing and the last group (no data)
when data were too inadequate to establish if the patient was treated or if the patient died shortly after counseling was
given. Causes of spinal cord injuries were many primary traumatic, innate and birth injuries and others. The large group
of “other” consists of a wide variety of acquired causes including benign tumors, vascular malformations or thrombosis,
degenerative and immune-mediated causes and postsurgical sequelae.
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therefore 138 isolates were included. Table 1 shows
the demographic data for the entire cohort. Com-
plete data were available for patients in the treated
and non-treated groups. Two patients from the
treated group and three patients from the non-trea-
ted group, with urinary diversion by intestinal seg-
ments, were excluded from the outcome analysis
because of missing data. In the last group of
patients (n = 9), the data are not adequate to estab-
lish whether treatment recommendations were fol-
lowed at all. Three patients died shortly after
counseling; the causes of death were lung edema
following sepsis, lung edema following heart failure
and in the last case unknown. In the analysis of
outcome, only the treated and non-treated groups
of patients are included.
Concerning the type of bladder drainage, 50%
(n = 64) of the patients used intermittent catheteri-
zation, 30% (n = 39) had indwelling catheters, and
10% (n = 13) had near-normal bladder emptying
whereas 10% (n = 13) used other methods [suprapu-
bic tapping, urosheath, Koch pouch and uretero ilio
cutaneostomia (a.m. Bricker)]. The proportion of
patients using intermittent and indwelling catheters
in the treated group was 52% (n = 42) and 27%
(n = 22), respectively. In the non-treated group,
41% (n = 11) used intermittent catheterization
whereas 37% (n = 10) used indwelling catheters. Of
the 138 isolates, the three most frequently found
microorganisms were E. coli (n = 75), Klebsiella sp.
(n = 28) and P. aeruginosa (n = 25). Other bacteria
were found in the rest of the isolates [Citrobacter sp.
(n = 3), Proteus sp. (n = 3), Enterobacter cloacae
(n = 3) and Enterococcus faecalis (n = 1)]. In an
analysis of the type of uropathogen found in rela-
tion to the type of bladder drainage method, it was
seen that of the 25 patients that had an infection
with P. aeruginosa, 68% (n = 17) had indwelling
catheters. This was only the case in 22% (n = 25) of
the patients with other uropathogens (p < 0.0001).
Table 2 shows the treated group (n = 79) and
non-treated group of patients (n = 24) in relation
to the number of chronic UTIs with speciﬁc uro-
pathogens.
Figure 1 shows the speciﬁc precipitating antibod-
ies before and after treatment in the treated group
and the non-treated group of patients. For the two
groups, we only had measured paired speciﬁc pre-
cipitating antibodies for 46 treated and nine non-
treated patients. This was especially due to lack of
measurement of follow-up speciﬁc precipitating
antibodies. In the treated group, there was a statis-
tically signiﬁcant decrease in the number of precipi-
tating antibodies after treatment (p < 0.02),
whereas this was not the case in the non-treated
patients. The follow-up was 3–12 months; the mean
time of follow-up was 6 months.
Figure 2 shows the change in the number of
speciﬁc precipitating antibodies in the treated and
non-treated groups. No diﬀerence in change in
speciﬁc precipitating antibodies was observed
between the two groups.
Table 3 shows the number of positive urine cul-
tures with the speciﬁc uropathogens that the
patients are chronically infected with, in relation to
the bladder emptying method. In the treated group,
there was a statistically signiﬁcant decrease in the
number of positive urine cultures after treatment;
in the non-treated group, the number of patients is
not enough for statistical analysis.
Ten patients had MDR isolates; eight of these
were E. coli and two were Klebsiella sp. Of the
eight patients with E. coli, six received recom-
mended long-term antibiotic treatment and three of
these MDR E. coli were not found again after
treatment was given. In the two patients with
E. coli that were in the non-treated group, one did
not have MDR E. coli again later. The two patients
with Klebsiella sp. were also in the non-treated
group; one patient did not have MDR Klebsiella
Table 2. Number of chronic infections and speciﬁc uropathogens
Entire cohort Escherichia coli Klebsiella sp. Pseudomonas
aeruginosa
Others1 Two
uropathogens2
Treated 79 49 14 7 4 5
Indwelling catheter 22 12 3 5 0 2
Intermittent
catheterization
42 28 9 2 1 2
Other methods 15 9 2 0 3 1
Non-treated 24 8 4 8 2 2
Indwelling catheter 10 1 3 3 1 2
Intermittent
catheterization
11 6 1 4 1 0
Other methods 3 1 0 1 0 0
Number of chronic infections and the responsible uropathogen in the treated (n = 79) and non-treated (n = 24) groups of
patients in relation to the bladder emptying methods.
1Others include Enterobacter cloacae, Citrobacter sp., Enterococcus faecalis and Proteus sp.
2Escherichia coli and Klebsiella sp. (n = 3), P. aeruginosa and E. coli (n = 4).
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sp. in the following urine samples. There were no
urine cultures from the other patient after the time
of counseling. There does not seem to be a diﬀer-
ence between treated and non-treated patients con-
cerning elimination of MDR bacteria but the data
are too limited to make conclusions. It is possible
that some patients in the non-treated group have
received antibiotic treatment other than that recom-
mended. Interestingly, no new MDR uropathogens
appeared in either group of patients.
DISCUSSION
UTI is a frequently seen medical condition in
patients with SCLs and especially chronic UTIs are
a great challenge in relation to treatment. There is
only one prospective study concerning chronic
UTIs in this patient population. Clayton et al. sug-
gest that antibiotic therapy appropriate to all mem-
bers of the complex microbial community in the
urine of SCL patients should be used to achieve
successful treatment (21). Studies of other groups
of patients with long-term catheterization do not
focus on the aspect of treatment (22–24). There is
no consensus on the treatment approach. In respect
to prevention of UTI with antibacterial agents, pre-
vious studies have shown a signiﬁcant decrease in
the incidence of UTI in SCL patients given weekly
oral cyclic antibiotics (alternate administration of
an antibiotic once a week, week A one type of
antibiotic and week B another type of antibiotic);
however, these studies only included patients using
intermittent catheterization (5, 25). Another study
has shown remarkable eﬃcacy of long-term low-
dose ciproﬂoxacin in the prevention of UTIs in
SCL patients, but only patients without indwelling
catheters were included (26). No studies concerning
prevention of UTI have been performed in chroni-
cally infected SCL patients with indwelling cathe-
ters.
The aim of the present evaluation in connection
to a mini review on bioﬁlms and UTIS was to ana-
lyze the eﬀect of long-term treatment with antibi-
otics in patients with SCL and chronic UTI. One
hundred twenty-nine patients over a 3-year period
were evaluated. UTI was deﬁned as chronic when
there was a positive urine culture and elevated
levels of speciﬁc precipitins (6), supported by
repeated positive urine cultures, recurrent UTI
symptoms and reduction in renal function.
The number of speciﬁc precipitating antibodies
decreased signiﬁcantly in the group of patients that
received the recommended treatment and there was
a trend toward a decrease in the number of positive
urine samples. The recommended antibiotic treat-
ment seemed eﬀective in the elimination of chronic
UTIs in SCL patients. The long-term treatment did
not seem to enhance the elimination of MDR
Fig. 2. Change in the number of speciﬁc precipitating
antibodies in the treated and non-treated groups. Compar-
ison of change in speciﬁc precipitating antibodies against
uropathogens from before treatment or recommended
treatment until 3–12 months after end of treatment or rec-
ommended treatment in the treated (n = 46) and non-trea-
ted (n = 9) groups. Line represents means and standard
deviations. There was no statistical signiﬁcance between
the changes in the two groups.
Fig. 1. Number of speciﬁc precipitating antibodies in the
treated and non-treated groups 6 months before treatment
and 3–12 months after counseling concerning treatment.
Patients chronically infected with more than one uro-
pathogen were not included. Data on paired speciﬁc pre-
cipitating antibodies were obtained from 46 treated
patients and nine non-treated patients. We found a signiﬁ-
cant (p < 0.02) decline in the number of speciﬁc precipitat-
ing antibodies in the treated group (n = 46). There was no
signiﬁcant change in the number of speciﬁc precipitating
antibodies in the group of non-treated patients (n = 9).
Line represents means and standard deviations.
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uropathogens; however, with the limited number, it
is diﬃcult to show a trend. More importantly, the
aggressive treatment strategy did not select new
MDR uropathogens.
An evaluation of outcome of novel treatment
and diagnostic strategies confers important limita-
tions. The single-center approach limits the number
of patients available; however, all SCL patients in
Eastern Denmark were followed up at this center
and thereby all other treatments they received were
according to the same guidelines. A detailed drug
history could not be obtained for all patients and it
is possible that some patients received antibiotic
treatment other than that recommended; however,
in the analysis, we only included patients who were
followed up regularly at the Clinic for Spinal Inju-
ries. Even though the patients were asked about the
antibiotic treatment, there may be information bias.
Furthermore, in many cases, there were limited
data from after counseling in relation to urine cul-
tures and precipitin values. It was possible to
obtain paired precipitating antibodies for 58% of
the patients in the treated group (n = 46) in con-
trast to only 38% of the patients in the non-treated
group (n = 9). This also inﬂuences the interpreta-
tion of the results on possible changes in speciﬁc
precipitating antibodies. There may be selection
bias in this analysis, as it is possible that patients in
the non-treated group were not followed up after
counseling due to compliance problems or that the
patients who no longer had UTI symptoms were no
longer motivated to have new blood and urine sam-
ples taken.
One could speculate that the group reluctant to
follow the treatment recommendations was also the
group less compliant. This can only be further clari-
ﬁed through a follow-up controlled study. In addi-
tion, the non-treated group could actually have
received a short antibiotic course by a private
practitioner, which potentially could inﬂuence our
results. With reference to the strategy used in CF
where chronically infected patients are treated four
times a year, our patients only received one antibi-
otic course (or no antibiotic course) with up to
12 months to experience a new UTI, which again
could induce production of precipitating antibodies.
The present results suggest that the long-term
treatment strategy is eﬀective, and measurement of
speciﬁc antibody response could be included as a
diagnostic marker of chronic bioﬁlm-related UTI.
However, randomized trials, with the possibility of
closer follow-up of the patients and more markers
of eﬀect and detailed and complete drug history,
are needed to conﬁrm this.
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